Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARTV | Common Stock | Conversion of derivative security | +844K | 844K | Jul 22, 2024 | Direct | F1, F2 | |||
transaction | ARTV | Common Stock | Conversion of derivative security | +215K | +25.45% | 1.06M | Jul 22, 2024 | Direct | F1, F2 | ||
transaction | ARTV | Common Stock | Other | +462K | +43.63% | 1.52M | Jul 22, 2024 | Direct | F2, F3 | ||
transaction | ARTV | Common Stock | Purchase | $5M | +417K | +27.41% | $12.00* | 1.94M | Jul 22, 2024 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARTV | Series A Convertible Preferred Stock | Conversion of derivative security | -844K | -100% | 0 | Jul 22, 2024 | Common Stock | 844K | Direct | F1, F2 | |||
transaction | ARTV | Series B Convertible Preferred Stock | Conversion of derivative security | -215K | -100% | 0 | Jul 22, 2024 | Common Stock | 215K | Direct | F1, F2 |
venBio Global Strategic Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. |
F2 | These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein. |
F3 | Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20. |
Dr. Aaron Royston is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III.